UY39555A - Terapia de células car-t dirigida a bcma para mieloma múltiple - Google Patents

Terapia de células car-t dirigida a bcma para mieloma múltiple

Info

Publication number
UY39555A
UY39555A UY0001039555A UY39555A UY39555A UY 39555 A UY39555 A UY 39555A UY 0001039555 A UY0001039555 A UY 0001039555A UY 39555 A UY39555 A UY 39555A UY 39555 A UY39555 A UY 39555A
Authority
UY
Uruguay
Prior art keywords
car
subject
multiple myeloma
bcma
cell therapy
Prior art date
Application number
UY0001039555A
Other languages
English (en)
Spanish (es)
Inventor
Mark Schecter Jordan
Xiaohu Fan
Original Assignee
Janssen Biotech Inc
Nanjing Legend Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Nanjing Legend Biotech Co Ltd filed Critical Janssen Biotech Inc
Publication of UY39555A publication Critical patent/UY39555A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
UY0001039555A 2020-12-03 2021-12-03 Terapia de células car-t dirigida a bcma para mieloma múltiple UY39555A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/133598 WO2022116086A1 (en) 2020-12-03 2020-12-03 Bcma-targeted car-t cell therapy for multiple myeloma

Publications (1)

Publication Number Publication Date
UY39555A true UY39555A (es) 2022-06-30

Family

ID=79270135

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039555A UY39555A (es) 2020-12-03 2021-12-03 Terapia de células car-t dirigida a bcma para mieloma múltiple

Country Status (15)

Country Link
US (3) US20220265710A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255450A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023551877A (cg-RX-API-DMAC7.html)
KR (1) KR20230118556A (cg-RX-API-DMAC7.html)
CN (1) CN116888147A (cg-RX-API-DMAC7.html)
AR (1) AR124248A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021392708A1 (cg-RX-API-DMAC7.html)
CA (1) CA3203603A1 (cg-RX-API-DMAC7.html)
IL (1) IL303312A (cg-RX-API-DMAC7.html)
JO (1) JOP20230122A1 (cg-RX-API-DMAC7.html)
MA (1) MA71426A (cg-RX-API-DMAC7.html)
MX (1) MX2023006371A (cg-RX-API-DMAC7.html)
TW (1) TW202237637A (cg-RX-API-DMAC7.html)
UY (1) UY39555A (cg-RX-API-DMAC7.html)
WO (2) WO2022116086A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12522645B2 (en) 2019-11-05 2026-01-13 Janssen Biotech, Inc. BCMA-targeted CAR-T cell therapy of multiple myeloma
AU2021266428A1 (en) * 2020-05-04 2023-01-19 Bio-Diagnostics Limited A diagnostic device
WO2024146398A1 (zh) * 2023-01-04 2024-07-11 北京艺妙神州医药科技有限公司 分离的抗体、包含该抗体的car及其用途
WO2024206329A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
CA3205511A1 (en) * 2023-04-19 2025-03-17 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2026090579A1 (en) 2024-10-25 2026-04-30 Janssen Biotech, Inc. Methods of treating smoldering multiple myeloma with ciltacabtagene autoleucel

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN105777911B (zh) * 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
US12048718B2 (en) * 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
PL3896091T3 (pl) * 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CN108395478A (zh) * 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
WO2019242632A1 (en) * 2018-06-19 2019-12-26 1§1Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
TW202020146A (zh) * 2018-07-26 2020-06-01 大陸商南京傳奇生物科技有限公司 含nef之t細胞及其產生方法

Also Published As

Publication number Publication date
JOP20230122A1 (ar) 2023-05-30
EP4255450A1 (en) 2023-10-11
US20260209308A1 (en) 2026-07-23
KR20230118556A (ko) 2023-08-11
MA71426A (fr) 2025-04-30
MX2023006371A (es) 2023-07-31
CA3203603A1 (en) 2022-06-09
CN116888147A (zh) 2023-10-13
US20240000836A1 (en) 2024-01-04
WO2022116086A1 (en) 2022-06-09
AU2021392708A1 (en) 2023-06-22
JP2023551877A (ja) 2023-12-13
AR124248A1 (es) 2023-03-01
TW202237637A (zh) 2022-10-01
WO2022117068A1 (en) 2022-06-09
US20220265710A1 (en) 2022-08-25
IL303312A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
MX2023006371A (es) Terapia de células car-t dirigida a bcma para mieloma múltiple.
MX2024005461A (es) Terapia de celulas car-t dirigida a bcma para mieloma multiple.
Maia et al. Effect of low-level laser therapy on pain levels in patients with temporomandibular disorders: a systematic review
WO2020092848A3 (en) Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
MX2016005666A (es) Anticuerpos anti-cd38 especificos para tratar canceres humanos.
AR087356A1 (es) Terapia de combinacion para el tratamiento de sintomas de tumores malignos de celulas b cd19que comprende inmunoconjugado maitansinoide anti-cd19 y rituximab
MX2022001623A (es) Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla.
MX2024005237A (es) Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo.
DOP2023000216A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
EP4151210A3 (en) Pyridine-carboline derivatives as mchr1 antagonists for use in therapy
AR044315A1 (es) Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido
AR122341A1 (es) Método para el tratamiento de cáncer utilizando célula adyuvante artificial (aavc)
MX2022009041A (es) Metodos de dosificacion y tratamiento de linfoma folicular y linfoma de zona marginal en terapia celular adoptiva.
Rothrock Management of chronic daily headache utilizing a uniform treatment pathway
PE20250161A1 (es) Dosis para tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3 en pacientes mayores
MX2022001153A (es) Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab.
Noguerado-Mellado et al. Anaphylactic shock due to brentuximab-vendotin confirmed by skin test and in vitro tests
MX2022001154A (es) Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab.
Barlogie Management of multiple myeloma
Hansen UAB-led study shows drug effectiveness in reducing glucocorticoid-induced bone loss
AR124317A1 (es) Tratamiento de pacientes con cáncer con terapias con linfocitos infiltrantes de tumor en combinación con inhibidores de braf y/o inhibidores de mek
AR131998A1 (es) Terapia celular para el tratamiento de enfermedades autoinmunes sistémicas
Park et al. The effect of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) chemotherapy in patients with ocular adnexal extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma
CO2025001817A2 (es) Método para tratar una enfermedad mediada por linfocitos t
Gross et al. Radiotherapy compared to extracorporeal shockwave therapy for supraspinatus tendinitis-randomised prospective single-blind trial with two-sample parallel group design